A trimethoprim conjugate of thiomaltose has enhanced

antibacterial efficacy in vivo.

Xiaojian Wang,^{†,//} Clarissa A. Borges,[‡] Xinghai Ning,[†] Mohammad Rafi,[†] Jingtuo Zhang,[†] Bora Park,[†] Kiyoko Takemiya,[#] Carlo Lo Sterzo,[†] W. Robert Taylor,^{#, §,⊥}Lee Ri-ley[‡] and Niren Murthy^{*,†}

[†]Department of Bioengineering, University of California, Berkeley, California 94720, United States

[#]Institute of Advanced Synthesis, School of Chemistry and Molecular Engineering, Jiangsu National Synergetic Innovation Center for Advanced Materials, Nanjing Tech University, Nanjing 211816, China

[‡]Department of Public Health, University of California, Berkeley, California 94720, United States

[#]Emory University School of Medicine, Department of Medicine, Division of Cardiology, Atlanta, Georgia 30322, United States

[§]Georgia Institute of Technology, Department of Biomedical Engineering, Atlanta, Georgia 30332, United States.

¹Atlanta Veterans Affairs Medical Center, Cardiology Division, Atlanta, Georgia 30033, United States

Email: nmurthy@berkeley.edu

SUPPLEMENTARY INFORMATION

ABBREVIATIONS

Ac	Acetyl
AcOH	Acetic acid
C	Carbon
CDCl ₃	Deuterated chloroform
CD ₃ OD	Deuterated methanol
CFU	Colony forming unit
CH ₃ CN	Acetonitrile
CuI	Copper iodide
DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC	N,N'-Dicyclohexylcarbodiimide
DCM/CH ₂ Cl ₂	Dichloromethane/Methylene chloride
DIPEA	N,N-Diisopropylethylamine
DI water	Deionized water
DMAP	4-Dimethylaminopyridine
DMF	N, <i>N</i> -Dimethylformamide
DMSO	Dimethyl sulfoxide
DMSO-d ₆	Deuterated Dimethyl sulfoxide
D ₂ O	Deuterium oxide
ESI	Electrospray ionization
EtOAc	Ethyl acetate
Н	Proton
HCl	Hydrogen chloride
H ₂ O	Water
HPLC	High-performance liquid chromatography
HRMS	High resolution mass spectrometry

Hz	Hertz
LB	Luria-Bertani
LiOH	Lithium hydroxide
М	Molar
MALDI	Matrix assisted laser desorption ionization spectroscopy
MeOH/CH ₃ OH	Methanol
mL	Milliliter
NaHCO ₃	Sodium bicarbonate
NaOH	Sodium hydroxide
NaSO ₄	Sodium sulfate
NMR	Nuclear magnetic resonance
N ₂	Nitrogen
OD	Optical density
PBS	
Ру	Pyridine
s.e.m	Standard error of the mean
TEA	Triethyl amine
TLC	Thin layer chromatography
UV	Ultraviolet
μL	Micro litter

EXPERIMENTAL PROCEDURES

¹H-NMR spectra were recorded in CDCl₃, CD₃OD, DMSO-d₆ or D₂O on a Bruker AVB-400 spectrometer at 298K. TMS (δ (*ppm*)_H = 0.00) was used as the internal refer-¹³C-NMR spectra were recorded in either CDCl₃, CD₃OD, DMSO-d₆ or D₂O at a ence. 100MHz on a Bruker AVB-400 spectrometer, using the central resonances of CDCl₃ (δ $(ppm)_C = 77.0$) and methanol (δ $(ppm)_C = 50.4$) as the internal references. Chemical shifts are reported in ppm and multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), and m (multiplet). Coupling constants, J, are reported in hertz (Hz). High-resolution mass spectra (HRMS) were obtained on a AB SCIEX TOF/TOF 5800 system and are reported as m/z (relative intensity). Accurate masses are reported for the molecular ion (M^+) or a suitable fragment ion. Chemicals and solvents were purchased from Sigma-Aldrich or VWR and used without further purification. Flash chromatography was carried out using silica gel (230-400 mesh). All reactions were performed under anhydrous conditions under N_2 or Argon and monitored by TLC on MD Millipore Silica Gel 60 F254 Glass Plates. Detection was accomplished by examination under UV light (254 nm) and by charring with 20 % sulfuric acid in methanol.

S1. Synthesis





Figure S1. Synthesis of compound 1.

To a stirred solution of 4-mercaptobutanoic acid (0.36 g, 3.0 mmol) in DCM (10 mL) was added 2-(but-3-yn-1-yldisulfanyl)pyridine (0.65 g, 3.3 mmol) in DCM (5 mL) and TEA (0.5 mL), and the reaction mixture was stirred at room temperature overnight under

N₂. The reaction was concentrated *in vacuo* and purified by flash column chromatography on silica gel (hexane/EtOAc/AcOH, 7:3:0.05) to afford **1** (0.34 g, 56%). ¹H NMR (400 MHz, CDCl₃): δ (*ppm*) 2.82 (t, *J* = 7.2 Hz, 2H), 2.76 (t, *J* = 7.0 Hz, 2H), 2.60 (td, *J* = 7.0, 2.3 Hz, 2H), 2.51 (t, *J* = 7.2 Hz, 2H), 2.13 – 1.99 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ (*ppm*) 178.7, 82.1, 69.6, 37.7, 37.1, 32.2, 23.9, 19.0. HRMS m/z Found: 203.0207, calculated: 203.0200 for C₈H₁₁O₂S₂ [*M*-H]⁻.

S1.2. Synthesis of Trimethoprim alkyne (2)



Figure S2. Synthesis of compound 2.

To a stirred suspension of 4'-OH-trimethoprim¹ (1.1 g, 3.8 mmol) and the acid **1** (0.31 g, 1.5 mmol) in DMF (10 mL) was added DCC (0.34 g, 1.6 mmol), DMAP (0.30 g, 2.4 mmol) and TEA (0.3 mL). The reaction mixture was stirred at room temperature overnight under N₂ and then 200 mL of EtOAc was added. The mixture was extracted with water (50 mL x 2) and brine (50 mL). The organic phase was dried over Na₂SO₄, filtered and evaporated to dryness *in vacuo*. The residue was purified by flash column chromatography on silica gel (5% MeOH in DCM) to afford **2** (193 mg, 28%). ¹H NMR (400 MHz, MeOD): δ (*ppm*) 7.55 (s, 1H), 6.57 (s, 2H), 3.76 (s, 6H), 3.69 (s, 2H), 2.85 (dm, 4H), 2.70 (t, J = 7.1 Hz, 2H), 2.59 (td, J = 7.1, 2.5 Hz, 2H), 2.32 (t, J = 2.6 Hz, 1H), 2.12 (m, 2H). ¹³C NMR (100 MHz, MeOD): δ (*ppm*) 172.9, 153.7, 138.6, 108.7, 106.4, 83.2, 70.9, 61.7, 56.8, 51.9, 40.6, 38.4, 34.6, 33.4, 33.2, 32.1, 27.1, 26.7, 26.2, 25.8,

19.8. HRMS m/z Found: 463.1461, calculated: 463.1474 for $C_{21}H_{27}N_4O_4S_2 [M+H]^+$.

S1.3 Synthesis of α-D-glucopyranose, 4-S-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl) -4-thio-2,3,6-triacetate (4).



Figure S3. Synthesis of compound 4.

Thiomaltose acetate was prepared following the reported method.² To a stirred solution of thiomaltose acetate (0.35 g, 0.50 mmol) in DMF (10 mL) was added N_2H_4 ·HOAc (46.0 mg, 0.50 mmol). The reaction mixture was kept at room temperature for 12 hours under nitrogen, and the mixture was concentrated *in vacuo*. The residue was dissolved in EtOAc (100 mL) and washed with water (30 mL x 2) and brine (30 The organic phase was dried over Na_2SO_4 , filtered and evaporated to dryness in mL). vacuo. The residue was purified by flash column chromatography on silica gel (hexane/EtOAc, 1:1) to afford 4 (α/β mixture, 1:1, 0.26 g, 82%). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 5.88 (m, 1H), 5.59 (t, J = 10.3 Hz, 0.5H), 5.39 (d, J = 3.4 Hz, 0.5H), 5.26 (m, 2H), 5.06 (m, 1H), 4.96 (m, 1H), 4.78 – 4.60 (m, 2H), 4.32 (m, 1H), 4.28 – 4.15 (m, 3H), 4.10 (m, 1H), 3.69 (m, 1H), 3.01 (m, 1H), 2.11-1.97 (m, 21 H). ¹³CNMR (100 MHz, CDCl₃): δ (ppm) 170.8, 170.6, 170.0, 169.9, 169.8, 169.5, 95.0, 90.3, 82.4, 75.1, 74.7, 72.8, 72.3, 72.2, 70.3, 69.8, 69.7, 68.5, 68.1, 67.9, 63.8, 63.5, 61.5, 43.8, 20.9, 20.8, 20.7, 20.6, 20.5, 20.5, 20.4. MS (HR-ESI) m/z Found: 675.1555, calculated: C₂₆H₃₆O₁₇SNa $[M+Na^+]$ 675.1571.

S1.4 Synthesis of α-D-glucopyranose, 3-azidopropyl 4-S-(2,3,4,6-tetra-O-acetyl-β-D -glucopyranosyl)-4-thio-2,3,6-triacetyl (6).



Figure S4. Synthesis of compound 6.

To a stirred solution of 4 (0.20 g, 0.31 mmol) in dry DCM (5 mL) was added trichloroacetonitrile (0.6 mL, 6.0 mmol), and the solution was cooled to 0 °C. DBU (23 µL, 0.15 mmol) was then added and the suspension was stirred at 0 °C for 6 hours under nitrogen. The reaction mixture was concentrated *in vacuo* to afford crude compound. The residue was purified by flash column chromatography on silica gel (hexane/EtOAc, 2:1) to afford 5 (0.18 g, 77%) and used immediately after purification. To a stirred solution of trichloroimidate 5 (0.16 g, 0.20 mmol) and 3-azidopropanol (0.10 g, 1.0 mmol) in dry DCM (5 mL) was added 4Å M.S. The mixture was stirred under nitrogen at 0 °C for 1 hour. TMSOTf (45 μ L, 0.22 mmol) was then added and the mixture was stirred at 0 °C for 2 hour. The reaction was quenched with Et_3N and concentrated *in vacuo*. The residue was dissolved in EtOAc (20 mL) and washed with water (5 mL x 2) and brine (10 The organic phase was dried over Na_2SO_4 , filtered and evaporated to dryness in mL). The residue was purified by flash column chromatography on silica gel (hexvacuo.

ane/EtOAc, 1:1) to afford **6** (93 mg, 63%). ¹H NMR (400 MHz, CDCl₃): δ (*ppm*) 5.87 (d, *J* = 5.9 Hz, 1H), 5.23 (dd, *J* = 19.0, 9.4 Hz, 2H), 5.04 (t, *J* = 9.8 Hz, 1H), 4.94 (dd, *J* = 10.4, 5.9 Hz, 1H), 4.77 (t, *J* = 9.8 Hz, 1H), 4.64 (dd, *J* = 11.8, 2.1 Hz, 1H), 4.44 (d, *J* = 8.0 Hz, 1H), 4.31 (dd, *J* = 12.5, 4.1 Hz, 1H), 4.25 - 4.14 (m, 2H), 4.09 (dd, *J* = 12.4, 1.7 Hz, 1H), 3.91 - 3.82 (m, 1H), 3.68 - 3.52 (m, 2H), 3.39 - 3.27 (m, 2H), 2.98 (t, *J* = 10.9 Hz, 1H), 2.11 - 2.01 (m, 21H), 1.86 - 1.75 (m, 2H). ¹³CNMR (100 MHz, CDCl₃): δ (*ppm*) 170.5, 170.4, 170.1, 170.0, 169.8, 169.5, 169.4, 100.3, 82.3, 75.7, 72.7, 72.6, 70.3, 69.7, 68.6, 67.9, 66.3, 63.6, 61.5, 47.9, 43.7, 28.9, 20.8, 20.7, 20.6, 20.6, 20.5, 20.4. HRMS (HR-ESI) m/z Found: 758.2035, calculated: 758.2054 for C₂₉H₄₁N₃O₁₇SNa [*M*+Na]⁺.

S1.5. Synthesis of Azidothiomaltose (7).



Figure S5. Synthesis of compound 7.

To a stirred solution of **6** (74 mg, 0.10 mmol) in anhydrous CH₃OH (5 mL) was added NaOCH₃ (5.4 mg, 1.0 mmol) under an atmosphere of N₂ at room temperature, and the stirring was continued at room temperature for 12 hours. The reaction mixture was neutralized by adding acidic resins (Dowex 50W, hydrogen form), filtrated, concentrated *in vacuo* and used in the following step without further purification. ¹H-NMR (400 MHz, MeOD): δ (*ppm*) 5.68 (d, 1H, *J* = 5.6 Hz), 4.28 (d, 1H, *J* = 8.0 Hz), 4.00-3.89 (m, 5H), 3.73-3.59 (m, 4H), 3.50-3.44 (m, 4H), 3.28-3.18 (m, 2H), 2.91-2.88 (m, 1H), 1.90-1.87 (m, 2H). ¹³C NMR (100 MHz, D₂O): δ (*ppm*) 102.8, 86.6, 77.1, 75.6, 74.6, 74.2, 73.7, 71.9, 66.1, 61.8, 61.3, 28.8. MS (MALDI) m/z Found: 464.1, calculated: C₁₅H₂₇N₃O₁₀SNa [M+Na⁺] 464.13.



S1.6. Synthesis of Thiomaltose-trimethoprim (3)

Figure S6. Synthesis of compound 3.

To a stirred solution of **7** (10 mg, 0.023 mmol) and trimethoprim alkyne **2** (10.6 mg, 0.023 mmol) in DMSO (2 mL) was added CuI (0.2 mg, 1 µmol) and DIPEA (1.2 mg, 0.093 mmol). The mixture was stirred at room temperature for 12 hours under nitrogen and then diluted with 20 mL of water, filtered and purified by HPLC to afford **3** (14.7 mg, 71%, >90% pure on HPLC). ¹H-NMR (400 MHz, D₂O): δ (*ppm*) 7.69 (s, 1H), 7.32 (s, 1H), 6.60 (s, 2H), 5.63 (d, J = 5.5 Hz, 1H), 4.37 (m, 2H), 4.26 (d, J = 7.9 Hz, 1H), 3.94 – 3.91 (m, 2H), 3.86 - 3.37 (m, 20H), 3.25 (t, J = 8.5 Hz, 1H), 3.08 - 2.86 (m, 4H), 2.81 - 2.59 (m, 5H), 2.12 - 1.92 (m, 4H). ¹³C NMR (100 MHz, D₂O): δ (*ppm*) 172.99, 164.40, 163.04, 162.68, 154.32, 151.74, 139.73, 135.86, 126.57, 123.55, 117.82, 109.00, 105.77, 102.13, 86.22, 76.22, 75.16, 74.10, 73.50, 73.03, 71.05, 69.46, 66.10, 61.56, 60.47, 56.13, 47.06, 37.13, 36.84, 32.72, 31.90, 29.69, 24.61, 24.10. HRMS (HR-ESI) m/z Found: 904.2862, calculated: 904.2891 for C₃₆H₅₄N₇O₁₄S₃ [*M*+Na]⁺.

S1.7. Synthesis of Thiomaltose-perylene.



Figure S7. Synthesis of compound TM-P.

To a stirred solution of 7 (10 mg, 0.023 mmol) and alkyne functionalized perylene dye^3 (13 mg, 0.041 mmol) in DMF (2 mL) was added CuI (0.2 mg, 1.0 $\mu mol)$ and DIPEA (1.2 mg, 0.093 mmol). The mixture was stirred at room temperature for 12 hours under nitrogen and then diluted with 20 mL of water, filtered and purified by HPLC to afford **TM-P** (13 mg, 75%, >90% pure on HPLC). ¹H-NMR (400 MHz, DMSO-d₆): δ (*ppm*) 7.85-7.76 (m, 3H), 7.72 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.13-7.03 (m, 4H), 5.96 (d, J = 6.0 Hz, 1H), 4.96-4.91 (m, 2H), 4.71 (m, 2H), 4.55 (s, 2H), 4.45 (d, J = 8.4 Hz, 1H), 3.78-3.71 (m, 5H), 3.69-3.67 (m, 2H), 3.43-3.31 (m, 5H), 3.22-3.20 (m, 3H), 2.91-2.89 (m, 1H), 1.91 (m, 2H). 13 C NMR (100

MHz, DMSO-d₆): δ (*ppm*) 143.3, 134.8, 133.1, 132.8, 131.9, 131.7, 131.0, 128.9 128.5, 127.9, 127.9, 126.7, 126.5, 126.1, 123.7, 123.6, 120.1, 120.04, 120.01, 119.5, 103.6, 97.8, 81.5, 79.1, 77.3, 76.9, 75.7, 73.8, 73.1, 72.8, 70.6, 68.1, 64.3, 62.0, 48.7, 47.9, 28.5. HRMS (HR-ESI) m/z Found: 784.2543, calculated: 784.2516 for C₃₉H₄₃N₃O₁₁SNa [*M*+Na]⁺.

S2. Serum Stability



Figure S8. Serum stability of MH-P.

To 146 μ L of FBS was added 4 μ L of 2.5 mM TM-P or MH-P. The solution was incubated at 37 °C and analyzed with HPLC at different time points. The column used for the HPLC analysis was an XBridge BEH C8 column (5 μ m, 4.6x150mm), and the elution was performed with 0.1% TFA in H₂O (A) and 0.1% TFA in acetonitrile (B). The gradient used was: 0-4 min, 5% B; 4-23 min, 5% to 100% B; 23-25 min, 100% B. The chromatography was monitored at 435 nm for the absorption of perylene. All peaks were integrated for the area and the % remaining TM-P or MH-P was calculated as: TM-P (or MH-P) peak area/the sum of all peak area.

S3. Metabolic Stability



Figure S9. HPLC chromatography of TM-P after bacterial uptake.

To a 1 mL suspension of *E. coli* in LB medium (OD600 = 0.6) was added 10 μ L of 2 mM TM-P. The mixture was incubated at 37 °C for 1 h and then centrifuged at 10000 rpm for 5 min. The supernatant was discarded and the cell pellet was washed with 1 mL of PBS for 3 times, via centrifugation. The cell pellet was then lysed with 200 μ L of bacteria lysis buffer and the supernatant was analyzed with HPLC using the same condition used in section S2. The intracellular concentration of TM-P (about 2.8 mM) was calculated based on the integrated area of TM-P comparing to TM-P standard and the approximate intracellular volume of 134 nanoliters per *E. coli*.

S4. Uptake of TM-IR780



Figure S10. A. Structure of TM-IR780. B. HPLC chromatography of TM-IR780 after

bacterial uptake.

To a 1 mL suspension of *E. coli* in LB medium (OD600 = 0.6) was added 2 μ L of 5 mM TM-IR780. The mixture was incubated at 37 °C for 1 h and then centrifuged at 10000 rpm for 5 min. The supernatant was discarded and the cell pellet was washed with 1 mL of PBS for 3 times, via centrifugation. The cell pellet was then lysed with 200 μ L of bacteria lysis buffer and the supernatant was analyzed with HPLC using the same condition used in section S2, except the chromatography was monitored at 650 nm for the absorption of IR780. The intracellular concentration of TM-IR780 (about 3.2 mM) was calculated based on the integrated area of TM-IR780 comparing to TM-IR780 standard and the approximate intracellular volume of 134 nanoliters per *E. coli*.

S5. Fluorescent image of TM-P treated E. coli

Figure S11. Fluorescent image of *E. coli* treated with TM-P.

E. coli (ATCC 33456) was incubated with 20 μ M of TM-P in LB broth at 37 °C for 1 h and then washed 3 times with PBS via centrifugation. Bacteria was then resuspended in PBS and observed under fluorescent microscope (Axioskop 2 with AxiCcam, Zeiss).

S6. Antibacterial activity of TMP-OH



Figure S12. Antibacterial activity of TMP-OH versus trimethoprim

To a 96-well plate containing 200 μ L of LB medium was added 1 μ L of *E. coli* (OD600 = 0.5) and 2 μ L of stock drug solution (TMP or TMP-OH) in DMSO. The plate was incubated at 37 °C, shaken at 190 rpm for 24 h, and the OD600 was measured using a Tecan Infinite 200 plate reader.





¹³C-NMR spectra of **TM-TMP**

-173.0 (* 65.2) (* 65.2) (* 65.2) (* 65.2) (* 65.2) (* 65.2) (* 65.2) (* 17.3) (* 65.2) (* 17.3) (* 17



References

- (1) Liu, W., Li, F., Chen, X., Hou, J., Yi, L., and Wu, Y.-W. (2014) A Rapid and Fluorogenic TMP-AcBOPDIPY Probe for Covalent Labeling of Proteins in Live Cells. J. Am. Chem. Soc. 136, 4468-4471.
- (2) Blanc-Muesser, M., Defaye, J., and Driguez, H. (1982) Stereoselective thioglycoside syntheses. Part 4. A new approach to 1,4-linked 1-thio-disaccharides and a synthesis of thiomaltose. *J. Chem. Soc., Perkin Trans.* 1, 15-18.
- Ning, X., Lee, S., Wang, Z., Kim, D., Stubblefield, B., Gilbert, E., and Murthy, N. (2011) Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. *Nat. Mater.* 10, 602-607.